Is Insight Molecular Diagnostics Inc. (IMDX) overvalued? · rev $1.9M
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
This page asks whether Insight Molecular Diagnostics Inc. (IMDX) looks expensive on cached numbers — not a short thesis.
Latest reported IMDX revenue for 2024-12-31 was $1.9M. Net income was -$60.7M. Revenue was up 25.1% from 2023-12-31 to 2024-12-31. IMDX currently screens at market cap $0.
IMDX currently screens at market cap $0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IMDX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IMDX stock page for the full model, not this heading.
Not investment advice.